Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03382405 · ClinicalTrials.gov registry record · Phase 1
Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults
A Phase 1 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 1
- Development phase
- 181
- Enrollment target
NCT03382405: Completed Phase 1 study, sponsored by ModernaTX.
NCT03382405 is a Phase 1 study that has completed, run by ModernaTX. The registered enrollment target is 181 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (202% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03382405, a Phase 1 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 181 participants
- Enrollment target
Study Summary
This clinical study will assess the safety, reactogenicity and immunogenicity of mRNA-1647 and mRNA-1443 cytomegalovirus vaccines in healthy adults
Interventions
- OTHER Placebo
- BIOLOGICAL mRNA-1647
- BIOLOGICAL mRNA-1443
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2017-11-13 |
| Est. Completion | 2020-10-28 |
| Phase | Phase 1 |
What the finished NCT03382405 record still lists
NCT03382405 is an interventional study that assigns participants to a tested intervention. The registered 181 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (202% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03382405 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03382405 about?
NCT03382405 is a clinical study titled "Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults". This clinical study will assess the safety, reactogenicity and immunogenicity of mRNA-1647 and mRNA-1443 cytomegalovirus vaccines in healthy adults
What is the current status of trial NCT03382405?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 181 participants. The study started on 2017-11-13. Estimated completion is 2020-10-28.
What interventions are being tested in trial NCT03382405?
The interventions under investigation include: Placebo (OTHER), mRNA-1647 (BIOLOGICAL), mRNA-1443 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03382405?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03382405's enrollment target sits among peer trials
181 299th of 2000 higher than 1,702 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04578392 · 181 participants · NA
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)
- NCT05597891 · 181 participants · NA
Endovascular Engineering ENGULF Study
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI